Fast Five Quiz: Advanced and Metastatic Breast Cancer Myths

Pavani Chalasani, MD, MPH; Stefania Morganti, MD


April 20, 2023

According to updated results from the phase 3 randomized RxPONDER study, postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer with one to three positive nodes and a 21-gene RS ≤ 25 (Oncotype DX) derive no further benefit from chemotherapy compared with endocrine therapy only. Conversely, premenopausal patients with the same clinical characteristics derive a ~5% absolute recurrence risk reduction from the addition of chemotherapy to endocrine therapy. However, whether the benefit is driven by chemotherapy itself or is mostly driven by chemotherapy-induced amenorrhea is debated.

Evidence suggests that chemotherapy does offer survival benefits for patients aged 70 years or older with TNBC. A recent study found that older women with TNBC who received chemotherapy had significantly improved survival compared with those who were recommended to undergo chemotherapy but did not receive it.

Learn more about adjuvant treatment for patients with early breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.